Skip to main content
Publications
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, Brown J, Dave V, Downey C, Shillington A, Katzenstein H, Kirker M, Hanson S, Liu F, Morris V, Bhanegaonkar A, Sonpavde G. Avelumab first-line maintenance (1LM) therapy for locally advanced/metastatic urothelial carcinoma (la/mUC): results from the realworld US PATRIOT-II study. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-a):S123.
Josa-Cullere A, Basagana X, Koch S, Arbillaga-Etxarri A, Balcells E, Bosch de Basea M, Celorrio N, Foraster M, Rodriguez-Roisin R, Marin A, Peralta GP, Rodriguez-Chiaradia DA, Simonet P, Toran-Monserrat P, Vall-Casas P, Garcia-Aymerich J. Short-term effects of air pollution and weather on physical activity in patients with chronic obstructive pulmonary disease (COPD). Environ Res. 2024 Apr;247:118195. doi: 10.1016/j.envres.2024.118195.
Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia-Esteban R, Plana E, Tormos A, Farsani SF, Perez-Gutthann S, Pladevall-Vila M. Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts. Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Anthony MS, Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B, Beachler DC, Crowe CL, Johannes CB, Juhaeri J, Lanes S, Pan C, Rothman KJ, Saltus CW, Walsh KE. Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study. Diabetes Care. 2024 Apr 1;47(4):712-9. doi: 10.2337/dc23-1911
Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
Neal J, Lee JB, Ahn MJ, Ariyasu R, nash C, Smith D, Nagar S, Jimenez M, Kahangire DA, Kim YJ, Nasirova F, Lin S. Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): interim analysis of a global real-world (RW) study. Poster presented at the European Lung Cancer Congress (ELCC) 2024; March 20, 2024. Prague, Czech Republic.
McElwee N, Willke R, Barrette E, Berger M, Cole A, Cortesi P, Earnshaw S, Garrison L, Gonzalez-Pier E, IJzerman M, Lee V, Hanson J, Mauskopf J, Reed S. Towards a vision for HEOR: opportunities for enhancement and evolution - an ISPOR health science policy council white paper. 2024. Available at: https://www.ispor.org/member-groups/councils-roundtables/health-science-policy-council. Accessed April 5, 2024.
Koch S, Peralta GP, Carsin AE, Abellan A, Roda C, Torrent M, Iniguez C, Ballester F, Ferrero A, Zabaleta C, Lertxundi A, Guxens M, Vrijheid M, Sunyer J, Casas M, Garcia-Aymerich J. Physical activity and body mass related to catch-up lung function growth in childhood: a population-based accelerated cohort study. Thorax. 2024 Mar 6. doi: 10.1136/thorax-2022-219666
Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2024; March 5, 2024. Lisbon, Portugal.
Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV, Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson R, Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med. 2024 Mar;30(3):650-9. doi: 10.1038/s41591-024-02827-9
Abellan A, Warembourg C, Mensink-Bout SM, Ambros A, de Castro M, Fossati S, Guxens M, Jaddoe VW, Nieuwenhuijsen MJ, Vrijheid M, Santos S, Casas M, Duijts L. Urban environment during pregnancy and lung function, wheezing, and asthma in school-age children. The generation R study. Environ Pollut. 2024 Mar 1;344:123345. doi: 10.1016/j.envpol.2024.123345
Craig T, Baptist AP, Anderson J, Vanegas A, Schultz BG, Blair C, Sing K, Juethner S. Quality of life among patients with hereditary angioedema within underrepresented racial or ethnic groups. Poster presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2024 Annual Meeting; February 4, 2024. Koloa, HI.
Tam S, Neslund-Dudas C, Barrett AM, Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis. Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Craig T, Baptist A, Anderson J, Zaragoza-Urdaz R, Burnette A, Kelbel T, Riedl M, Vanegas A, Boyle K, Schultz B, Blair C, Sing K, Fox D, Juethner S. Patient-reported outcomes among patients with hereditary angioedema within underrepresented racial or ethnic groups. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB81.
Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313